Stock comparison
ImmunityBio
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IBRX
ImmunityBio
Market cap
$7.56B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IBRX | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 31F | 71B | UTHR |
| Benjamin Graham | 45D | 76B | UTHR |
| Philip Fisher |
Side-by-side metrics
| Metric | IBRX | UTHR |
|---|---|---|
| Market cap | $7.56B | $24.13B |
| P/E (TTM) | - | 19.2x |
| EV/EBIT | - | 15.2x |
| ROIC (TTM) | -44.51% | 18.81% |
| Gross margin | 93.79% | 86.58% |
| Net margin | -6.06% | 40.61% |
| Revenue CAGR 5y | 2.32% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IBRX leads on
- P/E (TTM)-vs 19.2x+146%
- EV/EBIT-vs 15.2x+145%
- Debt / Equity-vs -+100%
- Revenue CAGR 5y2.32%vs 17.22%
More like UTHR
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.